Table 3. OS, local PFS, PFS before and after IPTW.
| Before IPTW | After IPTW | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TARE (n = 119) | TACE (n = 187) | P * | TACEinitial†(n = 148) | TACEhigh LSF†(n = 39) | P ‡ | TARE | TACE | P | |
| Median OS | 79.6 (NA–NA) | 46.5 (29.6–63.4) | 0.004 | 56.0 (35.4–76.6) | 20.3 (13.1–27.5) | 0.075 | 79.6 (69.3–NA) | 53.4 (40.1–75.6) | 0.033 |
| Median local PFS | 28.1 (16.1–40.1) | 9.3 (6.9–11.7) | 0.001 | 10.2 (7.9–12.4) | 5.5 (2.6–8.4) | 0.572 | 25.1 (14.2–NA) | 9.5 (7.8–13.6) | 0.001 |
| Median PFS | 11.7 (7.5–15.8) | 7.1 (5.5–8.7) | 0.017 | 8.8 (6.8–10.8) | 4.0 (3.3–4.7) | 0.005 | 9.8 (7.9–20.7) | 7.8 (6.4–10.2) | 0.066 |
Data are presented as months with the 95% confidence interval in parentheses.
*For comparing TARE (n = 119) and TACE (n = 187) over the entire follow-up period using the log-rank text, ‡For comparing TACEinitial (n = 148) and TACEhigh LSF (n = 39) over the entire follow-up period using the log-rank test, †TACEinitial and TACEhigh LSF indicate those who underwent TACE as initial treatment plan and patients who were initially planned for TARE but ultimately received TACE due to a high estimated lung dose, respectively.
OS = overall survival, PFS = progression-free survival, IPTW = inverse probability of treatment weighting, TACE = transarterial chemoembolization, LSF = lung shunt fraction, TARE = transarterial radioembolization, NA = not applicable